Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07214467 · ClinicalTrials.gov registry record · NA

Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder

A NA study of Substance Use Disorder (SUD) and Opioid Use Disorder (OUD), sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
6
Enrollment target
1
Study location

NCT07214467: Recruiting NA study of Substance Use Disorder (SUD) and Opioid Use Disorder (OUD), sponsored by University of California, San Francisco.

NCT07214467 is a NA study of Substance Use Disorder (SUD) and Opioid Use Disorder (OUD) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 6 participants, below the 249-participant average among 15 other Substance Use Disorder (SUD) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07214467, a NA study of Substance Use Disorder (SUD) and Opioid Use Disorder (OUD), is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if personalized (adaptive) Deep Brain Stimulation (DBS) based upon invasive brain mapping is safe and can lead to better outcomes like reductions in craving and opioid use.

Primary Outcome

To assess the safety of sEEG mapping in patients with severe and refractory OUD.

Conditions Studied

Substance Use Disorder (SUD) Opioid Use Disorder (OUD)

Interventions

  • DEVICE Deep Brain Stimulation

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2025-10-24
Est. Completion 2031-11-22
Phase NA
University of California, San Francisco

1,713 total trials

What NCT07214467 shows while recruiting

NCT07214467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 249-participant average among 15 other Substance Use Disorder (SUD) trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Substance Use Disorder (SUD) appearing as the primary indexed condition, and to 1 intervention - of which Deep Brain Stimulation is the first listed.

NCT07214467 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07214467 about?

NCT07214467 is a clinical study titled "Individualized Adaptive Deep Brain Stimulation in Opioid Use Disorder". The purpose of this study is to determine if personalized (adaptive) Deep Brain Stimulation (DBS) based upon invasive brain mapping is safe and can lead to better outcomes like reductions in craving and opioid use.

What is the current status of trial NCT07214467?

This trial is currently recruiting. It is a NA study. The enrollment target is 6 participants. The study started on 2025-10-24. Estimated completion is 2031-11-22.

What conditions does trial NCT07214467 study?

This clinical trial studies the following conditions: Substance Use Disorder (SUD), Opioid Use Disorder (OUD).

What interventions are being tested in trial NCT07214467?

The interventions under investigation include: Deep Brain Stimulation (DEVICE).

Who is sponsoring clinical trial NCT07214467?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07214467 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Substance Use Disorder (SUD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07214467's enrollment target sits among peer trials

6 16th of 15 the lowest of 15 other Substance Use Disorder (SUD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorder (SUD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07214467

Source: ClinicalTrials.gov NCT07214467, the US trial registry maintained by the National Library of Medicine. NCT07214467 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.